News

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...
NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.
Driven by a desire to help ex-servicemembers with post-traumatic stress disorder and other mental illnesses, GOP lawmakers ...
WHO issues alert on the use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy: Geneva Saturday, June 28, 2025, 11:00 Hrs [IST] WHO is alerting ...
As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...
Clinical Assessment Traumatic optic neuropathy is a clinical diagnosis and should not be made if vision and pupillary function are normal. There must be a history of trauma. The clinical history ...
Lack of pain Ischemic optic neuropathy, NMO-associated optic neuritis, LHON, Susac syndrome, various maculopathies Disc hemorrhages Ischemic optic neuropathy, inflammatory optic neuritis, (lupus ...
More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...
A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...
GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...